Physiomics PLC Partnership with TRHC's DoseMeRx(R) (9284I)
17 Diciembre 2020 - 8:00AM
UK Regulatory
TIDMPYC
RNS Number : 9284I
Physiomics PLC
17 December 2020
17 December 2020
Physiomics plc
("Physiomics" or "the Company")
Partnership with TRHC's DoseMeRx(R) Targeting Precision Dosing
for Oncology Medications
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions, today announces it
has entered into a partnership with Tabula Rasa HealthCare(R)
("TRHC") (NASDAQ:TRHC), a healthcare technology company advancing
the field of medication safety. Through this initiative,
Physiomics' personalised docetaxel model will be integrated into
TRHC's market-leading precision dosing solution, DoseMeRx(R). Both
parties expect positive feedback from this initial trial with the
next step being a commercial agreement.
Cancer remains one of the leading causes of death in developed
countries and one of the most significant areas of spend for health
systems. There are many effective cancer drugs; but, it is well
established that, given the same dose, variations between
individuals mean that different amounts of drug reach their
tumours.
Using measurements of the amount of drug in a patient's blood to
guide what dose they should receive has been shown to improve
efficacy and reduce side effects. The tests, however, are difficult
to obtain in oncology since they are expensive and not
standardised. Physiomics' personalised dosing models rely only on
inexpensive, standard blood tests that could help doctors and
pharmacists in making decisions about the dose of cancer drugs for
individual patients.
TRHC's DoseMeRx enables healthcare providers to optimise dosing
and streamline operations, reduce adverse drug events, and decrease
costs. The unique DoseMeRx platform incorporates Bayesian science
to guide the safe and effective dosing of 42 different drugs.
Physiomics Chief Executive Officer, Jim Millen, MD, said,
"Initially, we will focus on the drug docetaxel, which is commonly
used to treat prostate, breast and other cancers. However, one of
our goals is to establish how this could potentially be extended to
apply to other drugs and cancer types. We partnered with TRHC
because its DoseMeRx solution has been the leader in the
personalised dosing field for several years, and they have
demonstrated the ability to not only lead the science, but to make
it accessible for those who can benefit from it. We look forward to
the results of the trial and potentially entering into a revenue
generating contract in due course."
TRHC Chief Scientific Officer Jacques Turgeon, BPharm, PhD,
added, "The focus of the collaboration is on delivering better
outcomes for cancer patients. Incorporating this new science into
DoseMeRx will enable clinicians to more effectively predict the
timing of serious adverse effects, such as neutropenia, that are
commonly observed in patients receiving chemotherapy. We have seen
a great deal of success in infectious diseases through the use of
DoseMeRx, and we are excited to expand this into oncology."
Charles Cornish, TRHC's Executive Vice President, Hospital
Business Unit, said, "Through this partnership, we're bringing
together Physiomics' expertise in oncology precision medication
dosing with our experience in developing easy-to-use clinical
decision support software. Combined with our network of healthcare
providers throughout the United States and the world, this
partnership will further support the safe use of these medications
in clinical practice."
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0)20 3764 2341
TRHC Media Contact
Dianne L. Semingson
dsemingson@trhc.com
1+215-870-0829
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) (NASDAQ:TRHC) is a leader in
providing patient-specific, data-driven technology and solutions
that enable healthcare organizations to optimize performance to
improve patient outcomes, reduce hospitalizations, lower healthcare
costs, and manage risk. Medication risk management is TRHC's lead
offering, and its cloud-based software applications provide
solutions for a range of payers, providers, and other healthcare
organizations. For more information, visit TRHC.com
About DoseMeRx
DoseMeRx (R) is a Tabula Rasa HealthCare solution and the first
precision dosing software developed specifically for clinical
practice. DoseMeRx's clinical decision support solutions empower
healthcare providers to optimize dosing of high-risk parenteral
medications to streamline operations, reduce adverse drugs events,
decrease costs, and improve patient outcomes. For more information,
visit doseme-rx.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFZMMZGVKGGZZ
(END) Dow Jones Newswires
December 17, 2020 09:00 ET (14:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024